The Hunter Williams Podcast SGLT2 Inhibitors and GLP-1s | The Holy Grail of Longevity Medicine
16 snips
Nov 7, 2025 Explore the groundbreaking synergy between SGLT2 inhibitors and GLP-1 agonists that could redefine longevity medicine. Discover how these medications, initially designed for diabetes, offer unexpected benefits like improved cardiovascular health and kidney protection. Learn about the promising research linking SGLT2 use to reduced inflammation and potential longevity effects, along with insights on mouse studies and human outcomes. The conversation wraps up with practical tips on combining these therapies for optimal metabolic health.
AI Snips
Chapters
Books
Transcript
Episode notes
Possible Cancer Outcome Benefits
- Emerging analyses link SGLT2 use to lower overall cancer risk and much lower mortality in diabetic cancer patients.
- The drugs may create a less tumor‑friendly metabolic environment, but require cautious interpretation.
Mimicking Caloric Restriction
- SGLT2s mimic caloric restriction by activating AMPK, inhibiting mTOR, boosting FGF21, and inducing mild ketosis.
- This metabolic shift promotes autophagy, fat oxidation, and anti‑inflammatory ketone signaling.
Anti‑Inflammatory And Vascular Effects
- SGLT2 inhibitors lower inflammatory markers and improve vascular and tissue health across models.
- These anti‑inflammatory and endothelial benefits likely contribute to reduced chronic disease risk.
